SRR1330546
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.432
- INTERFERON_ALPHA_RESPONSE+0.414
- ANGIOGENESIS+0.396
- INFLAMMATORY_RESPONSE+0.387
- INTERFERON_GAMMA_RESPONSE+0.380
- ALLOGRAFT_REJECTION+0.370
- TNFA_SIGNALING_VIA_NFKB+0.302
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.296
- IL2_STAT5_SIGNALING+0.270
- COAGULATION+0.238
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.567
- HEDGEHOG_SIGNALING-0.416
- UNFOLDED_PROTEIN_RESPONSE-0.408
- MYC_TARGETS_V2-0.397
- DNA_REPAIR-0.379
- MTORC1_SIGNALING-0.372
- MYC_TARGETS_V1-0.362
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.352
- ADIPOGENESIS-0.321
- PROTEIN_SECRETION-0.305
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR608598 | GTEX | — | 0.962 |
| 2 | SRR615020 | GTEX | — | 0.943 |
| 3 | SRR602131 | GTEX | — | 0.938 |
| 4 | SRR1335047 | GTEX | — | 0.930 |
| 5 | SRR1361795 | GTEX | — | 0.929 |
| 6 | SRR1368964 | GTEX | — | 0.927 |
| 7 | SRR1488285 | GTEX | — | 0.924 |
| 8 | SRR1474795 | GTEX | — | 0.921 |
| 9 | SRR613114 | GTEX | — | 0.920 |
| 10 | SRR1335446 | GTEX | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.432 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.414 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.396 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.387 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.302 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.296 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| COAGULATION | 0.238 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.235 | Inavolisib | — uncovered |
| COMPLEMENT | 0.221 | Inavolisib | — uncovered |
| MYOGENESIS | 0.218 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.185 | Inavolisib | — uncovered |
| APOPTOSIS | 0.177 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.122 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.076 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.046 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.023 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |